(Q24245204)

4

0 references

Yulia Lin

1

object named as

Yulia Lin

0 references

Janet Birchall

3

object named as

Janet Birchall

0 references

Chris Hyde

Cochrane Database of Systematic Reviews

5

object named as

Chris Hyde

0 references

publication date

18 April 2007

0 references

published in

0 references

cites work

Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant activated factor VII in cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting--results of a single centre pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Hemostasis in liver resection surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant activated factor VII for acute intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Haemopoietic stem cell transplants: the impact of haemorrhagic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Activated recombinant factor VII in orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

rFVII for pediatric acute intracranial hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant factor VIIa should be used in massive obstetric haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant factor VIIa should be used in massive obstetric haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant factor VIIa for life-threatening post-partum haemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

21 January 2018

Ongoing NovoSeven trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

The use of recombinant factor VIIa in liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Transfusion medicine service policies for recombinant factor VIIa administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant factor VIIa in preterm neonates with prolonged prothrombin time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Potential role for rFVIIa in transfusion medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant FVIIa in the management of uncontrolled hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Factor VIIa (recombinant) for acute traumatic hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant factor VIIa (Novoseven) and the safety of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

The use of recombinant factor VIIa in the treatment of bleeding disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant activated factor VII in cardiac surgery: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant activated factor VII: a solution to refractory haemorrhage in vascular surgery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Haemostatic drug therapies for acute primary intracerebral haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Recombinant activated factor VII in cardiac surgery: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomiz

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Recombinant FVIIa for intractable hemorrhage: more questions than answers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB2

7 January 2021

10.1002/14651858.CD005011.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_zlatfpcubna4jldy4qidp5prcm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zlatfpcubna4jldy4qidp5prcm

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

17443565

1 reference

Consolidated OpenCitations Corpus – April 2017